BR112016023417A2 - predição in vitro de meia-vida in vivo - Google Patents

predição in vitro de meia-vida in vivo

Info

Publication number
BR112016023417A2
BR112016023417A2 BR112016023417-0A BR112016023417A BR112016023417A2 BR 112016023417 A2 BR112016023417 A2 BR 112016023417A2 BR 112016023417 A BR112016023417 A BR 112016023417A BR 112016023417 A2 BR112016023417 A2 BR 112016023417A2
Authority
BR
Brazil
Prior art keywords
antibody
fcrn
vivo half
retention time
life
Prior art date
Application number
BR112016023417-0A
Other languages
English (en)
Inventor
Emrich Thomas
Kettenberger Hubert
Schlothauer Tilman
Schoch Angela
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BR112016023417A2 publication Critical patent/BR112016023417A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B01D15/168—Fluid composition conditioning, e.g. gradient pH gradient, chromatofocusing, i.e. separation according to the isoelectric point pI
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

predição in vitro de meia-vida in vivo descreve-se neste contexto um método para a determinação da presença de interação de anticorpo fab-fcrn em um complexo de anticorpo-fc-fcrn que influencia a meia-vida in vivo que compreende as etapas de a) determinar o tempo de retenção do anticorpo em uma coluna de cromatografia de afinidade de fcrn com uma eluição de gradiente de ph linear positivo na presença de uma primeira concentração de cloreto de sódio, e b) determinação do tempo de retenção do anticorpo em uma coluna de cromatografia de afinidade de fcrn com uma eluição de gradiente de ph linear positiva na presença de uma segunda concentração de cloreto de sódio, pelo que é determinada a presença da interação de anticorpo-fab-fcrn em um complexo de anticorpo-fc-fcrn que influencia a meia-vida in vivo se o tempo de retenção determinado na etapa a) e o tempo de retenção determinado na etapa b) são substancialmente diferentes.
BR112016023417-0A 2014-03-21 2015-03-17 predição in vitro de meia-vida in vivo BR112016023417A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP14161103 2014-03-21
EP14161103.8 2014-03-21
EP14165987 2014-04-25
EP14165987.0 2014-04-25
PCT/EP2015/055482 WO2015140126A1 (en) 2014-03-21 2015-03-17 In vitro prediction of in vivo half-life of antibodies

Publications (1)

Publication Number Publication Date
BR112016023417A2 true BR112016023417A2 (pt) 2019-04-16

Family

ID=52684232

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016023417-0A BR112016023417A2 (pt) 2014-03-21 2015-03-17 predição in vitro de meia-vida in vivo

Country Status (10)

Country Link
US (2) US20170227547A1 (pt)
EP (1) EP3119490B1 (pt)
JP (2) JP6744855B2 (pt)
KR (1) KR20160134687A (pt)
CN (1) CN106103478B (pt)
BR (1) BR112016023417A2 (pt)
CA (1) CA2938722A1 (pt)
MX (1) MX2016011982A (pt)
RU (1) RU2688349C2 (pt)
WO (1) WO2015140126A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6152120B2 (ja) 2012-02-15 2017-06-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体に基づくアフィニティークロマトグラフィー
DK3042205T3 (da) * 2013-09-06 2020-03-02 Hoffmann La Roche Fremgangsmåde til forbedring af antistofstabilitet
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
CN106957364B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb12及其应用
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
EP3615678A1 (en) 2017-04-28 2020-03-04 H. Hoffnabb-La Roche Ag Antibody selection method
US20200047085A1 (en) * 2018-08-09 2020-02-13 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
MX2021003548A (es) 2018-10-01 2021-05-27 Hoffmann La Roche Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
CN112955240B (zh) * 2018-10-25 2022-09-16 豪夫迈·罗氏有限公司 抗体FcRn结合的修饰
JPWO2020116560A1 (ja) * 2018-12-05 2021-10-21 株式会社バイカ・セラピュティクス 抗体のＦｃ領域改変体
JP7241888B2 (ja) 2018-12-30 2023-03-17 エフ． ホフマン－ラ ロシュ アーゲー ｐＨ勾配ＳＰＲに基づく結合アッセイ
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
JP7322858B2 (ja) * 2020-11-02 2023-08-08 株式会社三洋物産 遊技機
JP7322857B2 (ja) * 2020-11-02 2023-08-08 株式会社三洋物産 遊技機
CN113308476B (zh) * 2021-05-12 2022-06-28 广东药康生物科技有限公司 一种FcRn基因人源化动物模型的构建方法
WO2022244838A1 (ja) * 2021-05-19 2022-11-24 中外製薬株式会社 分子のｉｎ ｖｉｖｏ薬物動態を予測する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545603A1 (en) * 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
KR101862402B1 (ko) * 2011-12-06 2018-05-30 삼성전기주식회사 도체 패턴 및 이를 포함하는 코일 부품
JP6152120B2 (ja) * 2012-02-15 2017-06-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体に基づくアフィニティークロマトグラフィー

Also Published As

Publication number Publication date
CA2938722A1 (en) 2015-09-24
RU2016137932A (ru) 2018-04-23
JP2017517745A (ja) 2017-06-29
CN106103478A (zh) 2016-11-09
US20170227547A1 (en) 2017-08-10
MX2016011982A (es) 2016-12-09
JP7032490B2 (ja) 2022-03-08
RU2016137932A3 (pt) 2018-10-29
RU2688349C2 (ru) 2019-05-21
JP6744855B2 (ja) 2020-08-19
KR20160134687A (ko) 2016-11-23
EP3119490B1 (en) 2021-09-08
WO2015140126A1 (en) 2015-09-24
EP3119490A1 (en) 2017-01-25
JP2020183967A (ja) 2020-11-12
US20210190795A1 (en) 2021-06-24
CN106103478B (zh) 2020-04-03

Similar Documents

Publication Publication Date Title
BR112016023417A2 (pt) predição in vitro de meia-vida in vivo
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
BR112018013677A2 (pt) proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
BR112018002848A2 (pt) método, aparelho, mídia de armazenamento não transitório, programa de computador, kit para medir níveis de expressão de seis ou mais genes-alvo da via de sinalização celular
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
BR112016016329A8 (pt) método para realizar cromatografia com resina de cromatografia irradiada com radiação gama e processo integrado, fechado, e contínuo para a produção de uma proteína recombinante purificada
CO2017009672A2 (es) Determinación del modo de derivación de información de movimiento en la codificación de video
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
BR112018002040A2 (pt) controle de uma nuvem de dispositivo
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
BR112016004415A2 (pt) método de tratamento de um paciente diagnosticado com um glioblastoma, uso de uma quantidade eficaz de um anticorpo anti-vegf, composição e kit
BR112014021897A2 (pt) nova fusão fgfr3
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
BR112015029986A8 (pt) Método para determinar equipamento óptico
BR112018008799A2 (pt) método de prognóstico
MX2018001536A (es) Metodo para la reduccion de proteinas de celulas hospederas en cromatografia de afinidad.
BR112017003627A2 (pt) ferramentas de produtividade para elaboração de conteúdo
BR112018000584A2 (pt) proteínas de fusão com ligação de dr5 multivalentes e multiespecíficas
BR112018010669A2 (pt) anticorpo anti-pcsk9 e utilização do mesmo
EA202091989A1 (ru) Способы лечения язвенного колита
BR112016024730A2 (pt) dispositivo, método e conjunto de análise imunocromatográfica
BR112014026440A2 (pt) assays, methods and apparatus for assessing rna disruption
NI201700022A (es) Anticuerpo anti-vasa y métodos de producción y uso de los mismos.
BR112018008749A2 (pt) métodos de detecção de apolipoproteína
BR112014032916A2 (pt) anticorpos anti-fármacos e usos destes para o monitoramento de fármaco

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]